UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003685
Receipt number R000004464
Scientific Title Association between serum vitamin D level and response to antiviral therapy with peginterferon and ribavirin in patients with chronic hepatitis C.
Date of disclosure of the study information 2010/06/02
Last modified on 2018/12/07 23:01:50

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Association between serum vitamin D level and response to antiviral therapy with peginterferon and ribavirin in patients with chronic hepatitis C.

Acronym

Association between serum vitamin D level and response to antiviral therapy with peginterferon and ribavirin in patients with chronic hepatitis C.

Scientific Title

Association between serum vitamin D level and response to antiviral therapy with peginterferon and ribavirin in patients with chronic hepatitis C.

Scientific Title:Acronym

Association between serum vitamin D level and response to antiviral therapy with peginterferon and ribavirin in patients with chronic hepatitis C.

Region

Japan


Condition

Condition

Chronic hepatitis C

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To elucidate the clinical significance of serum vitamin D level in the antiviral therapy of patients with chronic hepatitis C with peginterferon and ribavirin.

Basic objectives2

Others

Basic objectives -Others

Measurement of pretreatment serum vitamin D level in patients who underwent antiviral therapy with peginterferon and ribavirin. Comparison between pretreatment serum vitamin D level and treatment outcome.

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Comparison between pretreatment serum vitamin D level and treatment outcome.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with chronic hepatitis C who underwent antiviral therapy with peginterferon and ribavirin and individuals for whom the clinical backgrounds were matched with patients with chronic hepatitis C (as controls).

Key exclusion criteria

None

Target sample size

300


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Osamu Kozawa

Organization

Gifu University Graduate School of Medicine

Division name

Department of Pharmacology

Zip code


Address

Yanagito 1-1, Gifu, Gifu, Japan 501-1194

TEL

058-230-6214

Email

okozawa@gifu-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Rie Nishiwaki

Organization

Gifu University Graduate School of Medicine

Division name

Department of Pharmacology

Zip code


Address

Yanagito 1-1, Gifu, Gifu, Japan 501-1194

TEL

058-230-6217

Homepage URL


Email

riemn@gifu-u.ac.jp


Sponsor or person

Institute

Department of Pharmacology, Gifu University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2010 Year 06 Month 02 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2010 Year 02 Month 15 Day

Date of IRB


Anticipated trial start date

2010 Year 02 Month 15 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

retrospective study


Management information

Registered date

2010 Year 05 Month 31 Day

Last modified on

2018 Year 12 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004464


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name